-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Lynch syndrome (Lynch syndrome (LS)) is an inherited cancer susceptibility syndrome caused by mutations in four mismatch repair (MMR) genes: MLH1, MSH2, PMS2 and MSH6.
Lynch syndrome (Lynch syndrome (LS)) is an inherited cancer susceptibility syndrome caused by mutations in four mismatch repair (MMR) genes: MLH1, MSH2, PMS2 and MSH6.
Researchers collected clinical data of LS patients with pathogenic mismatch repair (MMR) gene variants from the LS registry of the National Cancer Center Hospital of Japan, and then used the Kaplan-Meier method to estimate the cumulative risk of gastric tumors, including development The incidence of ill health and cancer.
immunity
Of the 118 eligible LS patients, 26 patients were diagnosed with gastric tumors.
diagnosis
Through this retrospective study, the authors found that: for LS patients, especially patients with atrophic gastritis,Gastric cancer has a high risk of occurrence and often develops into multiple tumors.
Through this retrospective study, the authors found that: for LS patients, especially patients with atrophic gastritis,Gastric cancer has a high risk of occurrence and often develops into multiple tumors.
Original source:
Hourin Cho.
springer.
com/article/10.
1007/s10120-020-01113-0" target="_blank" rel="noopener">Gastric cancer is highly prevalent in Lynch syndrome patients with atrophic gastritis.
Leave a message here
